Heron Therapeutics Reports Q4 Revenue of $40.5M, Up 1.6% YoY

sábado, 10 de enero de 2026, 9:36 am ET1 min de lectura
HRTX--

Heron Therapeutics reported Q4 revenue of $40.5M, beating consensus of $39.83M. ZYNRELEF, a treatment for acute care, contributed $12.5M in revenue, while APONVIE, a treatment for postoperative nausea and vomiting, contributed $3.8M. CINVANTI, another treatment, generated $22.9M in revenue. The company's net revenue for FY25 was $154.9M.

Heron Therapeutics Reports Q4 Revenue of $40.5M, Up 1.6% YoY

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios